CTC is a certified Clario site for Expert Precision QT assessment (EPQT). EPQT is a cost‑effective technique that allows for QT interval assessment with higher accuracy by utilizing state-of-the-art algorithms and digital data processing early in the drug development lifecycle. Compared to conventional measuring, EPQT analyses approximately ten times more ECG data.
Using EPQT, it is possible to assess cardiac safety already during a routine Phase I study, thereby reducing the risk of encountering safety and regulatory issues in a later stage of drug development. The highly precise method reduces the number of subjects needed to exclude even small effects of the investigational product on the QT interval. Moreover, generation of early phase EPQT data might enable you to qualify for a TQT waiver, which drastically cuts development costs and time to market approval.
Our medical and scientific advisors can help you select the best strategy for your study design, and our well-trained site personnel will conduct the EPQT assessments in our clinical research units.